Table 1.

Patient Characteristics and Outcomes

Patient	Age	Sex	Karyotype and molecular findings	% Marrow blasts at diagnosis	Day 14 bone marrow	Induction outcome	Postinduction therapy and outcome
1002	63	M	+8, t(9:11), FLT3 TKD	93	<5% cellularity; NED	CR	Three cycles of IDAC consolidation off study followed by allogeneic stem cell transplant in CR1.
1003	46	M	t(12,13)	6.4	<5% cellularity; NED	Failure	Allogeneic transplant after salvage therapy.
1004	74	M	add(8) t(8,19) FLT3 TKD	64	Suboptimal; NED	CR	Two cycles of IDAC consolidation and relapse 6 mo after diagnosis.
							Postrelapse therapy on an experimental protocol and died of cerebral hemorrhage.
1005	46	M	XY (SNP array)	26	Suboptimal; serous atrophy; NED	CR	Four cycles of HiDAC + CX-01 consolidation on study.
							Relapse 16 mo after diagnosis. Underwent salvage therapy and allogeneic transplant. Had extramedullary relapse posttransplant and underwent salvage therapy and donor lymphocyte infusion.
1006	71	F	inv(3) FLT3 ITD	59	<5% cellularity; serous atrophy; NED	CR MRD	Two cycles of IDAC consolidation off study followed by allogeneic stem cell transplant in CR1.
							Relapse 9 mo after diagnosis, received further therapy on an experimental protocol and died of infectious complications.
1007	58	M	inv(16) +8, +22, +21	51	<5% cellularity serous atrophy; NED	CR MRD	Four cycles of HiDAC consolidation off study because of incomplete induction cycle.
1009	54	M	XY - NPM1+	37	10% cellularity; NED	CR	Three cycles of consolidation with HiDAC + CX-01 on study
							One cycle of consolidation with HiDAC alone after withdrawing from study.
1010	52	M	XY - FLT3 ITD	30	<5% cellularity serous atrophy; NED	CR	Developed line-associated deep vein thrombosis and went off study after induction. –
							Two cycles of HiDAC consolidation off study followed by allogeneic stem cell transplant in CR1.
2001	54	M	t(6,9) - FLT3 ITD	70	Not done	CR	Received 2 d of induction and relapsed 7 wk after diagnosis.
							Underwent salvage therapy and allogeneic stem cell transplant. Subsequently died of transplant-related complications.
3001	22	F	XX - NPM1 +	21	<10% cellularity; NED	CR	One cycle of HiDAC + CX-01 consolidation on study and was lost to follow-up after withdrawing study.
							Relapsed 13.5 mo after diagnosis, received salvage therapy and underwent allogeneic stem cell transplant in second remission.
3002	67	M	del(20) (q11.2) - FLT3 ITD (tested at relapse)	50	Hypocellular; NED	CR	Three cycles of consolidation therapy off study.
							Relapsed 11.5 mo after diagnosis. Underwent salvage therapy with transient response and relapse followed by allogeneic stem cell transplant.
3003	25	F	XX	69	<20% cellularity; NED	CR	Two cycles of HiDAC + CX-01 consolidation on study.
							Relapsed 6 mo after diagnosis and underwent salvage therapy and allogeneic stem cell transplant. Subsequently relapsed again and underwent salvage and second allogeneic stem cell transplant and died of transplant-related complications.

HiDAC, high-dose cytarabine; IDAC, intermediate-dose cytarabine; MRD, minimal residual disease; NED, no evidence of disease.